Pharmaceutical Technology on MSN
Recursion CEO details novel Phase III endpoint for rare disease drug
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results